אוסטרליה - אנגלית - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ceva animal health pty ltd - potassium aspartate; magnesium aspartate; nicotinic acid; di-isopropylamine dichloroacetate; sodium selenite; adenosine triphosphate - parenteral liquid/solution/suspension - potassium aspartate amino acid-aspartate active 20.0 mg/ml; magnesium aspartate amino acid-aspartate active 20.0 mg/ml; nicotinic acid alkaloid active 20.0 mg/ml; di-isopropylamine dichloroacetate ungrouped active 50.0 mg/ml; sodium selenite mineral-selenium active 0.5 mg/ml; adenosine triphosphate nucleotide active 2.0 mg/ml - cardiovascular system - dog | horse | bitch | castrate | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at - vascular system reactant | cardiac stimulant | coronary vasodilator | navicular disease | reactants on vascular system | respiratory stimulant | tick paralysis | vascular system | vasodilation

האיחוד האירופי - אנגלית - EMA (European Medicines Agency)

merck sharp dohme ltd - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - pelzont is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl)cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).pelzont should be used in patients in combination with 3-hydroxy-3-methylglutaryl-coenzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol lowering effect of hmg-coa-reductase inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with pelzont.

האיחוד האירופי - אנגלית - EMA (European Medicines Agency)

merck sharp dohme ltd. - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - tredaptive is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).tredaptive should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol-lowering effect of hmg-coa-reductase inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with tredaptive.

האיחוד האירופי - אנגלית - EMA (European Medicines Agency)

merck sharp dohme ltd - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - trevaclyn is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).trevaclyn should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol-lowering effect of hmg-coa-reductase-inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with trevaclyn.

קנדה - אנגלית - Health Canada

stanley pharmaceuticals, a division of vita health products inc. - nicotinic acid - tablet - 100mg - nicotinic acid 100mg - vitamin b complex

קנדה - אנגלית - Health Canada

stanley pharmaceuticals, a division of vita health products inc. - nicotinic acid - tablet - 500mg - nicotinic acid 500mg - vitamin b complex

קנדה - אנגלית - Health Canada

vita health products inc - nicotinic acid - tablet - 100mg - nicotinic acid 100mg - vitamin b complex

קנדה - אנגלית - Health Canada

valeant canada lp / valeant canada s.e.c. - nicotinic acid - tablet - 100mg - nicotinic acid 100mg - vitamin b complex

קנדה - אנגלית - Health Canada

anabolic laboratories inc. - nicotinic acid - capsule (sustained-release) - 300mg - nicotinic acid 300mg - vitamin b complex

קנדה - אנגלית - Health Canada

valeant canada lp / valeant canada s.e.c. - nicotinic acid - tablet - 500mg - nicotinic acid 500mg - vitamin b complex